Published in Gut on June 01, 2006
Nitric oxide and peroxynitrite in health and disease. Physiol Rev (2007) 15.49
Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med (2009) 7.53
Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87
Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. Lancet (2015) 2.74
Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis (2010) 2.62
Inflammatory bowel diseases phenotype, C. difficile and NOD2 genotype are associated with shifts in human ileum associated microbial composition. PLoS One (2012) 1.82
Comparative genetic analysis of inflammatory bowel disease and type 1 diabetes implicates multiple loci with opposite effects. Hum Mol Genet (2010) 1.81
Variation in treatment of patients with inflammatory bowel diseases at major referral centers in the United States. Clin Gastroenterol Hepatol (2014) 1.80
Defective leukocyte GM-CSF receptor (CD116) expression and function in inflammatory bowel disease. Gastroenterology (2011) 1.73
Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics. Gut Liver (2010) 1.51
Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.46
Racial differences in disease activity and quality of life in patients with Crohn's disease. Dig Dis Sci (2014) 1.44
Radiation exposure from diagnostic imaging studies among patients with inflammatory bowel disease in a safety-net health-care system. Dig Dis Sci (2013) 1.42
IDO1 and IDO2 non-synonymous gene variants: correlation with crohn's disease risk and clinical phenotype. PLoS One (2014) 1.40
Inflammatory Bowel Disease: How Effective Is TNF-α Suppression? PLoS One (2016) 1.39
Characteristics of inflammatory bowel disease serology in patients with indeterminate colitis. J Clin Gastroenterol (2014) 1.39
Identification of Candidate Adherent-Invasive E. coli Signature Transcripts by Genomic/Transcriptomic Analysis. PLoS One (2015) 1.38
Immunopathology of inflammatory bowel disease. World J Gastroenterol (2014) 1.36
Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol (2012) 1.34
Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J Immunol (2008) 1.33
Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci (2011) 1.30
Circulating microRNA is a biomarker of pediatric Crohn disease. J Pediatr Gastroenterol Nutr (2011) 1.29
Histopathological findings of extra-ileal manifestations at initial diagnosis of Crohn's disease-related ileitis. Virchows Arch (2016) 1.28
Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology (2010) 1.26
Vitamin D deficiency in children with inflammatory bowel disease. Dig Dis Sci (2011) 1.18
Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. PLoS One (2009) 1.16
Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients. Inflamm Bowel Dis (2010) 1.14
Prevalence of inflammatory bowel disease in two districts of Sri Lanka: a hospital based survey. BMC Gastroenterol (2010) 1.13
Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis (2010) 1.11
High levels of proinflammatory cytokines, but not markers of tissue injury, in unaffected intestinal areas from patients with IBD. Mediators Inflamm (2009) 1.09
Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut (2007) 1.09
Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig Dis Sci (2008) 1.08
Crohn's disease in Korea: past, present, and future. Korean J Intern Med (2014) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Alterations in diversity of the oral microbiome in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2011) 1.03
Investigation of the enteric pathogenic potential of oral Campylobacter concisus strains isolated from patients with inflammatory bowel disease. PLoS One (2012) 1.03
Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan. J Gastroenterol (2010) 1.02
Old-age inflammatory bowel disease onset: a different problem? World J Gastroenterol (2011) 1.00
Strong evidence of a combination polymorphism of the tyrosine kinase 2 gene and the signal transducer and activator of transcription 3 gene as a DNA-based biomarker for susceptibility to Crohn's disease in the Japanese population. J Clin Immunol (2009) 0.99
Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data. Gut Liver (2015) 0.98
Characteristics and trends in the incidence of inflammatory bowel disease in Korean children: a single-center experience. Dig Dis Sci (2009) 0.98
Defective tumor necrosis factor release from Crohn's disease macrophages in response to Toll-like receptor activation: relationship to phenotype and genome-wide association susceptibility loci. Inflamm Bowel Dis (2012) 0.98
Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res (Hoboken) (2012) 0.97
NOD2 status and human ileal gene expression. Inflamm Bowel Dis (2010) 0.96
Granulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's disease. Inflamm Bowel Dis (2013) 0.96
Association between toll-like receptors/CD14 gene polymorphisms and inflammatory bowel disease in Korean population. J Korean Med Sci (2011) 0.96
Anti-Saccharomyces cerevisiae antibody does not differentiate between Crohn's disease and intestinal tuberculosis. Dig Dis Sci (2006) 0.96
Long-Term Disease Course and Pregnancy Outcomes in Women with Inflammatory Bowel Disease: An Indian Cohort Study. Dig Dis Sci (2016) 0.96
Short- and long-term efficacy of endoscopic balloon dilation in Crohn's disease strictures. World J Gastroenterol (2013) 0.96
Association of age at diagnosis and Crohn's disease phenotype. Age Ageing (2012) 0.95
The polymorphism rs3024505 proximal to IL-10 is associated with risk of ulcerative colitis and Crohns disease in a Danish case-control study. BMC Med Genet (2010) 0.95
Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. J Transl Med (2015) 0.94
Inflammatory bowel disease unclassified. J Zhejiang Univ Sci B (2011) 0.94
Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open (2014) 0.94
Characterization of adherent bacteroidales from intestinal biopsies of children and young adults with inflammatory bowel disease. PLoS One (2013) 0.93
Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J Gastroenterol (2014) 0.93
Anti-Tumor Necrosis Factor-α Antibody Therapy Management Before and After Intestinal Surgery for Inflammatory Bowel Disease: A CCFA Position Paper. Inflamm Bowel Dis (2015) 0.93
Old age at diagnosis is associated with favorable outcomes in korean patients with inflammatory bowel disease. Intest Res (2015) 0.92
PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging (2007) 0.92
Histological evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.92
Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol (2009) 0.92
Involvement of endoplasmic reticulum stress in inflammatory bowel disease: a different implication for colonic and ileal disease? PLoS One (2011) 0.92
Risk factors for surgical recurrence after ileocolic resection of Crohn's disease. Dis Colon Rectum (2008) 0.92
Mucosal barrier in ulcerative colitis and Crohn's disease. Gastroenterol Res Pract (2013) 0.91
Milk fat globule-epidermal growth factor 8 is decreased in intestinal epithelium of ulcerative colitis patients and thereby causes increased apoptosis and impaired wound healing. Mol Med (2012) 0.91
Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol (2011) 0.91
Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg (2012) 0.91
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol (2016) 0.90
STAT3 genotypic variation and cellular STAT3 activation and colon leukocyte recruitment in pediatric Crohn disease. J Pediatr Gastroenterol Nutr (2012) 0.90
Race and inflammatory bowel disease in an urban healthcare system. Dig Dis Sci (2010) 0.90
Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-α Antibody Use: 35 Years of Experience at a Single Institute in Korea. Ann Coloproctol (2015) 0.89
Clinical literature review of 1858 Crohn's disease cases requiring surgery in China. World J Gastroenterol (2015) 0.89
Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease. J Immunol (2015) 0.89
Contribution of higher risk genes and European admixture to Crohn's disease in African Americans. Inflamm Bowel Dis (2012) 0.88
Molecular reclassification of Crohn's disease by cluster analysis of genetic variants. PLoS One (2010) 0.88
The risk of colorectal cancer in patients with ulcerative colitis. Dig Dis Sci (2014) 0.88
Relationship between vagal tone, cortisol, TNF-alpha, epinephrine and negative affects in Crohn's disease and irritable bowel syndrome. PLoS One (2014) 0.88
Microbiota separation and C-reactive protein elevation in treatment-naïve pediatric granulomatous Crohn disease. J Pediatr Gastroenterol Nutr (2012) 0.88
Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J Gastroenterol (2008) 0.88
Association of single nucleotide polymorphisms of IL23R and IL17 with ulcerative colitis risk in a Chinese Han population. PLoS One (2012) 0.88
Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. Am J Gastroenterol (2014) 0.87
Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunol (2010) 0.87
Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients. World J Gastroenterol (2015) 0.87
Selenium, selenoprotein genes and Crohn's disease in a case-control population from Auckland, New Zealand. Nutrients (2012) 0.87
C-reactive protein levels during a relapse of Crohn's disease are associated with the clinical course of the disease. World J Gastroenterol (2008) 0.87
Genetic polymorphisms of interleukin 17A and interleukin 17F and their association with inflammatory bowel disease in a Chinese Han population. Inflamm Res (2013) 0.87
Bowel perfusion measured with dynamic contrast-enhanced ultrasound predicts treatment outcome in patients with Crohn's disease. Inflamm Bowel Dis (2014) 0.87
Replication and meta-analysis of 13,000 cases defines the risk for interleukin-23 receptor and autophagy-related 16-like 1 variants in Crohn's disease. Can J Gastroenterol (2010) 0.87
Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol (2015) 0.86
Colonoscopic evaluation in ulcerative colitis. Gastroenterol Rep (Oxf) (2014) 0.85
Natural history of Crohn's disease following total colectomy and end ileostomy. Inflamm Bowel Dis (2014) 0.85
Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol (2015) 0.85
Fecal calprotectin level correlated with both endoscopic severity and disease extent in ulcerative colitis. BMC Gastroenterol (2016) 0.85
The positive influences of increasing age at diagnosis of inflammatory bowel disease on disease prognostication in asian perspective. Intest Res (2015) 0.85
Influence of Crohn's disease risk alleles and smoking on disease location. Dis Colon Rectum (2011) 0.85
Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn's disease: a meta-analysis. Dig Dis Sci (2012) 0.85
The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. J Crohns Colitis (2016) 0.84
Serum adipokines in inflammatory bowel disease. World J Gastroenterol (2014) 0.84
Risk factors for repeat abdominal surgery in korean patients with Crohn's disease: a multi-center study of a korean inflammatory bowel disease study group. J Korean Soc Coloproctol (2012) 0.84
Serological investigation of food specific immunoglobulin G antibodies in patients with inflammatory bowel diseases. PLoS One (2014) 0.84
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis (2000) 6.90
Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology (2004) 4.42
Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut (2001) 4.23
The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology (2002) 4.20
Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology (1994) 3.81
Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet (2000) 3.52
Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology (2005) 3.41
Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol (2004) 3.28
Lack of common NOD2 variants in Japanese patients with Crohn's disease. Gastroenterology (2002) 2.71
Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology (2002) 2.66
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Overlap in the spectrum of non-specific inflammatory bowel disease--'colitis indeterminate'. J Clin Pathol (1978) 2.56
Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol (2004) 2.53
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun (2004) 1.94
Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis (2005) 1.55
Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology (2005) 1.49
Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology (2000) 1.40
Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur J Hum Genet (2003) 1.30
Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet (2001) 11.12
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut (2010) 4.50
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther (2012) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut (2006) 3.57
Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet (2000) 3.52
Long-term outcome of endoscopic dilatation in patients with Crohn's disease is not affected by disease activity or medical therapy. Gut (2009) 3.50
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut (2008) 3.14
Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology (2001) 2.81
Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut (2008) 2.60
Characterisation of complementary and alternative medicine use and its impact on medication adherence in inflammatory bowel disease. Aliment Pharmacol Ther (2011) 2.33
Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol (2008) 2.28
Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut (2009) 2.08
Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol (2001) 2.06
Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther (2013) 2.05
Predicting relapse in Crohn's disease: a biopsychosocial model. Gut (2008) 2.01
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis (2008) 1.99
Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther (2004) 1.87
Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology (1997) 1.84
The changing pattern of Crohn's disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988-2007). Aliment Pharmacol Ther (2011) 1.69
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther (2013) 1.69
Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut (2005) 1.65
Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut (2009) 1.65
Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther (2004) 1.62
Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther (2014) 1.56
The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun (2007) 1.50
[Celiac disease in adults: new aspects]. Rev Med Interne (2004) 1.49
Review article: influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther (2010) 1.45
The Dutch guidelines for treatment with infliximab for Crohn's disease. Neth J Med (2006) 1.44
Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy (2009) 1.41
Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli strains isolated from patients with Crohn's disease. Aliment Pharmacol Ther (2003) 1.40
A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol (2002) 1.38
Letter: dry blood spots for anti-TNF treatment monitoring in IBD. Aliment Pharmacol Ther (2013) 1.37
The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther (2005) 1.34
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther (2004) 1.33
Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Aliment Pharmacol Ther (2013) 1.32
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.32
Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut (2009) 1.31
Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther (2006) 1.31
Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut (2005) 1.26
One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther (2012) 1.24
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis (2009) 1.22
Opposite evolution in incidence of Crohn's disease and ulcerative colitis in Northern France (1988-1999). Gut (2004) 1.20
Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn's disease. Genes Immun (2001) 1.20
A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut (2003) 1.19
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis (2011) 1.18
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther (2010) 1.18
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2010) 1.18
Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut (2005) 1.17
Systematic review: fertility in non-surgically treated inflammatory bowel disease. Aliment Pharmacol Ther (2013) 1.15
Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther (2004) 1.13
Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut (2007) 1.09
ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut (2005) 1.08
Epithelioid granulomas, pattern recognition receptors, and phenotypes of Crohn's disease. Gut (2005) 1.08
Inflammatory bowel disease in spouses and their offspring. Gastroenterology (2001) 1.05
Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease. Aliment Pharmacol Ther (2011) 1.05
Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther (2005) 1.05
Validation of 16S rDNA sequencing in microdissected bowel biopsies from Crohn's disease patients to assess bacterial flora diversity. J Pathol (2006) 1.04
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol (2002) 1.03
Infliximab failure in cap polyposis. Gut (2005) 1.02
Dysplasia and cancer in inflammatory bowel disease 10 years after diagnosis: results of a population-based European collaborative follow-up study. Digestion (2007) 1.01
Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut (2005) 0.99
Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther (2014) 0.98
Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol Ther (2011) 0.98
Impact of lipoteichoic acid modification on the performance of the probiotic Lactobacillus rhamnosus GG in experimental colitis. Clin Exp Immunol (2010) 0.96
Extractible self-expandable metal stent in the treatment of Crohn's disease anastomotic strictures. Endoscopy (2012) 0.95
CARD4/NOD1 is not involved in inflammatory bowel disease. Gut (2003) 0.94
Review article: infliximab for Crohn's disease treatment--shifting therapeutic strategies after 10 years of clinical experience. Aliment Pharmacol Ther (2011) 0.92
Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis. Gut (2006) 0.91
MAST3: a novel IBD risk factor that modulates TLR4 signaling. Genes Immun (2008) 0.90
Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther (2012) 0.90
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment. Gut (2011) 0.90
The IL-10R1 S138G loss-of-function allele and ulcerative colitis. Genes Immun (2008) 0.89
Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? Acta Gastroenterol Belg (2009) 0.87
Analysis of the CC chemokine receptor 5 (CCR5) delta-32 polymorphism in inflammatory bowel disease. Hum Genet (2001) 0.87
FISH analysis of Lactobacillus biofilms in the gastrointestinal tract of different hosts. Lett Appl Microbiol (2011) 0.87
Structural, functional, and genetic characterization of Gastrophilus hemoglobin. J Biol Chem (1998) 0.86
Mannan binding lectin (MBL) gene polymorphisms are not associated with anti-Saccharomyces cerevisiae (ASCA) in patients with Crohn's disease. Gut (2006) 0.86
Familial and sporadic inflammatory bowel disease: different entities? Inflamm Bowel Dis (2000) 0.86
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther (2011) 0.86
Clinical value of the detection of antibodies in the serum for diagnosis and treatment of inflammatory bowel disease. Gastroenterology (1998) 0.85
Gender-stratified analysis of DLG5 R30Q in 4707 patients with Crohn disease and 4973 controls from 12 Caucasian cohorts. J Med Genet (2007) 0.85
Profile of pediatric Crohn's disease in Belgium. J Crohns Colitis (2013) 0.84
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther (2010) 0.84
Outcome of surgery for rectovaginal fistula due to Crohn's disease. Br J Surg (2009) 0.84
Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis. Gut (2011) 0.84
Independent control of the production of insulin-like growth factor I and its binding protein by cultured testicular cells. Mol Cell Endocrinol (1990) 0.83
Extended haplotype association study in Crohn's disease identifies a novel, Ashkenazi Jewish-specific missense mutation in the NF-κB pathway gene, HEATR3. Genes Immun (2013) 0.83
Association of baseline C-reactive protein and prior anti-tumor necrosis factor therapy with need for weekly dosing during maintenance therapy with adalimumab in patients with moderate to severe Crohn's disease. Curr Med Res Opin (2013) 0.83
Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment Pharmacol Ther (2006) 0.83
Lymphatics, tertiary lymphoid organs and the granulomas of Crohn's disease: an immunohistochemical study. Aliment Pharmacol Ther (2011) 0.82
Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Aliment Pharmacol Ther (2012) 0.82
Prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis. Aliment Pharmacol Ther (2014) 0.81